Drug Trial Radar · NCT04330300
Coronavirus (COVID-19) ACEi/ARB Investigation
Last checked: Nov 19, 2026Latest source record: Jun 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
2,414
Planned (sponsor's estimate)
Start
Apr 30, 2020
Primary completion
Jul 31, 2021
Study completion Dec 1, 2021
Sponsor
- Lead sponsor
- National University of Ireland, Galway, IrelandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is known to require the angiotensin-converting enzyme 2 (ACE-2) receptor for uptake into the human body, there have been questions about whether medications that upregulate ACE-2 receptors might increase the risk of infection and subsequent complications. One such group of medications are anti-hypertensives that block the renin-angiotensin system, including both angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB). Both ACEi and ARB are widely used for the treatment of hypertension. Early reports from China and Italy suggest that many of those who die from COVID-19 have a coexisting history of hypertension. Consequently, there have been questions raised as to whether these 2 types of blood pressure medication might increase the risk of death among patients with COVID-19. However, it is well known that the prevalence of hypertension increases linearly with age. Therefore, it is possible that the high prevalence of hypertension and ACEi/ARB use among persons who die from COVID-19 is simply confounded by age (older people are at risk of both a history of hypertension and dying from COVID-19). Whether these commonly prescribed blood pressure medications increase the risk of COVID-19 or not remains unanswered. Statements from professional cardiology societies on both sides of the Atlantic have called for urgent research into this question. Our study aims to randomize patients with primary (essential) hypertension who are already taking ACEi/ARB to either switch to an alternative BP medication or continue with the ACEi/ARB that they have already been prescribed. Adults with compelling indications for ACEi/ARB will not be enrolled.
Conditions
- Hypertension
- COVID-19
Interventions
Thiazide or Thiazide-like diureticsDrug
Anti-hypertensive (Active Arm)
Calcium Channel BlockersDrug
Anti-hypertensive (Active Arm)
ACE inhibitorDrug
Anti-hypertensive (Control Arm)
Angiotensin receptor blockerDrug
Anti-hypertensive (Control Arm)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Galway
Galway, Ireland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.